Published in Asian J Androl on June 17, 2013
Urine Cell-Free DNA Integrity Analysis for Early Detection of Prostate Cancer Patients. Dis Markers (2015) 0.80
Cancer statistics, 2013. CA Cancer J Clin (2013) 84.72
Screening and prostate-cancer mortality in a randomized European study. N Engl J Med (2009) 35.94
Mortality results from a randomized prostate-cancer screening trial. N Engl J Med (2009) 30.05
Prostate-cancer mortality at 11 years of follow-up. N Engl J Med (2012) 16.91
Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. J Natl Cancer Inst (2012) 11.91
Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med (2008) 8.14
Natural history of early, localized prostate cancer. JAMA (2004) 7.44
A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med (1989) 7.01
Comorbidity and mortality results from a randomized prostate cancer screening trial. J Clin Oncol (2010) 4.84
Screening decreases prostate cancer death: first analysis of the 1988 Quebec prospective randomized controlled trial. Prostate (1999) 4.12
Screening decreases prostate cancer mortality: 11-year follow-up of the 1988 Quebec prospective randomized controlled trial. Prostate (2004) 4.02
Declines in prostate cancer incidence after changes in screening recommendations. Arch Intern Med (2012) 3.53
Prostate-specific antigen screening for prostate cancer and the risk of overt metastatic disease at presentation: analysis of trends over time. Cancer (2012) 2.98
Assessing contamination and compliance in the prostate component of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. Clin Trials (2010) 2.38
Use of the prostate-specific antigen test among U.S. men: findings from the 2005 National Health Interview Survey. Cancer Epidemiol Biomarkers Prev (2008) 1.95
Serum prostate specific antigen as pre-screening test for prostate cancer. J Urol (1992) 1.84
Maximal androgen blockade: final analysis of EORTC phase III trial 30853. EORTC Genito-Urinary Tract Cancer Cooperative Group and the EORTC Data Center. Eur Urol (1998) 1.61
Diagnosis of advanced or noncurable prostate cancer can be practically eliminated by prostate-specific antigen. Urology (1996) 1.56
Prostate cancer mortality reduction by screening: power and time frame with complete enrollment in the European Randomised Screening for Prostate Cancer (ERSPC) trial. Int J Cancer (2002) 1.41
Can combined androgen blockade provide long-term control or possible cure of localized prostate cancer? Urology (2002) 1.12
Blockade of testicular and adrenal androgens in prostate cancer treatment. Nat Rev Urol (2011) 1.06
Combination therapy with flutamide and castration (LHRH agonist or orchiectomy) in advanced prostate cancer: a marked improvement in response and survival. J Steroid Biochem (1985) 1.02
The case for androgen deprivation as primary therapy for early stage disease: results from J-CaP and CaPSURE. J Urol (2006) 0.92
Efficacy of primary hormonal therapy for patients with localized and locally advanced prostate cancer: a retrospective multicenter study. Int J Urol (2006) 0.92
Prostate-cancer mortality after PSA screening. N Engl J Med (2012) 0.92
Effect of the correction for noncompliance and contamination on the estimated reduction of metastatic prostate cancer within a randomized screening trial (ERSPC section Rotterdam). Int J Cancer (2010) 0.89
Relationship among initial serum prostate specific antigen, prostate specific antigen progression and prostate cancer detection at repeat screening visits. J Urol (2006) 0.82